202. Mulligan, C.; Kondakala, S.; Yang, E.J.; Stokes, J.V.; Stewart, J.A.; Kaplan, B.L.; Howell, G.E., 3rd. Exposure to an environmentally relevant mixture of organochlorine compounds and polychlorinated biphenyls Promotes hepatic steatosis in male Ob/Ob mice. *Environ. Toxicol.* **2016**. [CrossRef]

203. Migliaccio, V.; Scudiero, R.; Sica, R.; Lionetti, L.; Putti, R. Oxidative stress and mitochondrial uncoupling protein 2 expression in hepatic steatosis induced by exposure to xenobiotic DDE and high fat diet in male Wistar rats. *PLoS ONE* **2019**, *14*, 1-24. [CrossRef] [PubMed]

204. Rodriguez-Alcala, L.M.; Sa, C.; Pimentel, L.L.; Pestana, D.; Teixeira, D.; Faria, A.; Calhau, C.; Gomes, A. Endocrine disruptor DDE associated with a high-fat diet enhances the impairment of liver fatty acid composition in rats. *J. Agric. Food Chem.* **2015**. [CrossRef]

205. Howell III, G.; Mulligan, C.; Meek, E.; Chambers, J.E.; State, M.; State, M. Effect of chronic p,p'-dichlorodiphenyldichloroethylene (DDE) exposure on high fat diet-induced alterations in glucose and lipid metabolism in male C57BL/6H mice. *Toxicology* **2019**, 112-122. [CrossRef]

206. La Merrill, M.; Karey, E.; Moshier, E.; Lindtner, C.; La Frano, M.R.; Newman, J.W.; Buettner, C. Perinatal exposure of mice to the pesticide DDT impairs energy expenditure and metabolism in adult female offspring. *PLoS ONE* **2014**, *9*, 1-11. [CrossRef]

207. Wang, D.; Wang, X.; Zhang, P.; Wang, Y.; Zhang, R.; Yan, J.; Zhou, Z.; Zhu, W. The fate of technical-grade chlordane in mice fed a high-fat diet and its roles as a candidate obesogen. *Environ. Pollut.* **2017**, *222*, 532-542. [CrossRef]

208. Xiao, X.; Sun, Q.; Kim, Y.; Yang, S.H.; Qi, W.; Kim, D.; Yoon, K.S.; Clark, J.M.; Park, Y. Exposure to permethrin promotes high fat diet-induced weight gain and insulin resistance in male C57BL/6J mice. *Food Chem. Toxicol.* **2018**, *111*, 405-416. [CrossRef]

209. Liang, Y.; Zhan, J.; Liu, D.; Luo, M.; Han, J.; Liu, X.; Liu, C.; Cheng, Z.; Zhou, Z.; Wang, P. Organophosphorus pesticide chlorpyrifos intake promotes obesity and insulin resistance through impacting gut and gut microbiota. *Microbiome* **2019**, *7*, 1-15. [CrossRef]

210. Fang, B.; Li, J.W.; Zhang, M.; Ren, F.Z.; Pang, G.F. Chronic chlorpyrifos exposure elicits diet-specific effects on metabolism and the gut microbiome in rats. *Food Chem. Toxicol.* **2018**, *111*, 144-152. [CrossRef]

211. Migliaccio, V.; Di Gregorio, I.; Putti, R.; Lionetti, L. Mitochondrial involvement in the adaptive response to chronic exposure to environmental pollutants and high-fat feeding in a rat liver and testis. *Cells* **2019**, *8*, 834. [CrossRef] [PubMed]

212. Claus, S.P.; Guillou, H.; Ellero-Simatos, S. The gut microbiota: A major player in the toxicity of environmental pollutants? *NPJ Biofilms Microbiomes* **2016**, *2*, 16003. [CrossRef] [PubMed]

213. Tsiaoussis, J.; Antoniou, M.N.; Koliarakis, I.; Mesnage, R.; Vardavas, C.I.; Izotov, B.N.; Psaroulaki, A.; Tsatsakis, A. Effects of single and combined toxic exposures on the gut microbiome: Current knowledge and future directions. *Toxicol. Lett.* **2019**, *312*, 72-97. [CrossRef] [PubMed]

214. Yim, Y.J.; Seo, J.; Kang, S.I.; Ahn, J.H.; Hur, H.G. Reductive dechlorination of methoxychlor and DDT by human intestinal bacterium Eubacterium limosum under anaerobic conditions. *Arch. Environ. Contam. Toxicol.* **2008**, *54*, 406-411. [CrossRef] [PubMed]

215. Liu, Q.; Wang, Q.; Xu, C.; Shao, W.; Zhang, C.; Liu, H.; Jiang, Z.; Gu, A. Organochloride pesticides impaired mitochondrial function in hepatocytes and aggravated disorders of fatty acid metabolism. *Sci. Rep.* **2017**, *7*, 1-11. [CrossRef]

216. Mao, Q.; Manservisi, F.; Panzacchi, S.; Mandrioli, D.; Menghetti, I.; Vornoli, A.; Bua, L.; Falcioni, L.; Lesseur, C.; Chen, J.; et al. The Ramazzini Institute 13-week pilot study on glyphosate and roundup administered at human-equivalent dose to Sprague Dawley rats: Effects on the microbiome. *Environ. Health Glob. Access Sci. Source* **2018**, *17*, 1-12. [CrossRef]

217. Mesnage, R.; Oestreicher, N.; Poirier, F.; Nicolas, V.; Boursier, C.; Vélot, C. Transcriptome profiling of the fungus Aspergillus nidulans exposed to a commercial glyphosate-based herbicide under conditions of apparent herbicide tolerance. *Environ. Res.* **2020**, *182*, 109116. [CrossRef] [PubMed]

218. Serino, M.; Luche, E.; Gres, S.; Baylac, A.; Bergé, M.; Cenac, C.; Waget, A.; Klopp, P.; Iacovoni, J.; Klopp, C.; et al. Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota. *Gut* **2012**, *61*, 543-553. [CrossRef]

219. Yan, A.; Fouts, D.; Brandl, J.; Starkel, P.; Torralba, M.; Schott, E.; Tsukamoto, H.; Nelson, K.; Brenner, D.; Schnabl, B. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. *Hepatology* **2011**, *53*, 96-105. [CrossRef]
220. Selmanoğlu, G. Carbendazim-induced haematological, biochemical and histopathological changes to the liver and kidney of male rats. *Hum. Exp. Toxicol.* **2001**, *20*, 625–630. [CrossRef]

221. Jin, Y.; Wang, L.; Chen, G.; Lin, X.; Miao, W.; Fu, Z. Exposure of mice to atrazine and its metabolite diaminochlorotriazine elicits oxidative stress and endocrine disruption. *Environ. Toxicol. Pharmacol.* **2014**, *37*, 782–790. [CrossRef] [PubMed]

222. Chavez-Tapia, N.C.; Lizardi-Cervera, J.; Perez-Bautista, O.; Ramos-Ostos, M.H.; Uribe, M. Smoking is not associated with nonalcoholic fatty liver disease. *World J. Gastroenterol.* **2006**, *12*, 5196–5200. [PubMed]

223. Akhavan Rezayat, A.; Dadgar Moghadam, M.; Ghasemi Nour, M.; Shirazinia, M.; Ghodsi, H.; Rouhbakhsh Zahmatkesh, M.R.; Tavakolizadeh Noghabi, M.; Hoseini, B.; Akhavan Rezayat, K. Association between smoking and non-alcoholic fatty liver disease: A systematic review and meta-analysis. *SAGE Open Med.* **2018**, *6*, 205031211774522. [CrossRef] [PubMed]

224. Petroni, M.L.; Brodosi, L.; Marchignoli, F.; Musio, A.; Marchesini, G. Moderate alcohol intake in non-alcoholic fatty liver disease: To drink or not to drink? *Nutrients* **2019**, *11*, 3048. [CrossRef] [PubMed]

225. Cioboaț, R.; Găman, A.; Trașcă, D.; Ungureanu, A.; Docea, A.O.; Tomescu, P.; Gherghina, F.; Arsene, A.L.; Badiu, C.; Tsatsakis, A.M.; et al. Pharmacological management of non-alcoholic fatty liver disease: Atorvastatin versus pentoxifylline. *Exp. Ther. Med.* **2017**, *13*, 2375–2381. [CrossRef]

226. Chen, Z.; Tian, R.; She, Z.; Cai, J.; Li, H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. *Free Radic. Biol. Med.* **2020**, *152*, 116–141. [CrossRef]

227. Omokaro, S.O.; Golden, J.K. The regulatory state of nonalcoholic steatohepatitis and metabolism. *Endocrinol. Diab. Metab.* **2020**, *3*, e00113. [CrossRef]

228. Farrell, G.; Schattenberg, J.M.; Leclercq, I.; Yeh, M.M.; Goldin, R.; Teoh, N.; Schuppan, D. Mouse models of nonalcoholic steatohepatitis: Toward optimization of their relevance to human nonalcoholic steatohepatitis. *Hepatology* **2019**, *69*, 2241–2257. [CrossRef]

229. Santhekadur, P.K.; Kumar, D.P.; Sanyal, A.J. Preclinical models of non-alcoholic fatty liver disease. *J. Hepatol.* **2018**, *68*, 230–237. [CrossRef]

230. Jahn, D.; Kircher, S.; Hermanns, H.M.; Geier, A. Animal models of NAFLD from a hepatologist's point of view. *Biochim. Biophys. Acta Mol. Basis Dis.* **2019**, *1865*, 943–953. [CrossRef]

231. Ore, A.; Akinloye, O.A. Oxidative stress and antioxidant biomarkers in clinical and experimental models of non-alcoholic fatty liver disease. *Medicina* **2019**, *55*, 26. [CrossRef] [PubMed]

232. Świderska, M.; Maciejczyk, M.; Zalewska, A.; Pogorzelska, J.; Flisiak, R.; Chabowski, A. Oxidative stress biomarkers in the serum and plasma of patients with non-alcoholic fatty liver disease (NAFLD). Can plasma AGE be a marker of NAFLD? Oxidative stress biomarkers in NAFLD patients. *Free Radic. Res.* **2019**, *53*, 841–850. [CrossRef] [PubMed]

233. Kim, H.J.; Lee, Y.; Fang, S.; Kim, W.; Kim, H.J.; Kim, J.-W. GPx7 ameliorates non-alcoholic steatohepatitis by regulating oxidative stress. *BMB Rep.* **2020**. [CrossRef]

234. Simon, J.; Nuñez-García, M.; Fernández-Tussy, P.; Barbier-Torres, L.; Fernández-Ramos, D.; Gómez-Santos, B.; Buqué, X.; Lopitz-Otsoa, F.; Goikoetxea-Usandizaga, N.; Serrano-Macia, M.; et al. Targeting hepatic glutaminase 1 ameliorates non-alcoholic steatohepatitis by restoring very-low-density lipoprotein triglyceride assembly. *Cell Metab.* **2020**, *31*, 605–622.e10. [CrossRef]

235. Milaciu, M.V.; Vesa Ştefan, C.; Bocşan, I.C.; Ciumărnean, L.; Sâmpelean, D.; Negrean, V.; Pop, R.M.; Matei, D.M.; Paşca, S.; Răchişan, A.L.; et al. Paraoxonase-1 serum concentration and PON1 gene polymorphisms: Relationship with non-alcoholic fatty liver disease. *J. Clin. Med.* **2019**, *8*, 2200. [CrossRef]

236. Shin, S.K.; Cho, H.W.; Song, S.E.; Song, D.K. Catalase and nonalcoholic fatty liver disease. *Pflugers Arch. Eur. J. Physiol.* **2018**, *470*, 1721–1737. [CrossRef]

237. Hwang, I.; Uddin, M.J.; Pak, E.S.; Kang, H.; Jin, E.J.; Jo, S.; Kang, D.; Lee, H.; Ha, H. The impaired redox balance in peroxisomes of catalase knockout mice accelerates nonalcoholic fatty liver disease through endoplasmic reticulum stress. *Free Radic. Biol. Med.* **2020**, *148*, 22–32. [CrossRef]

238. Nerstedt, A.; Kurhe, Y.; Cansby, E.; Caputo, M.; Gao, L.; Vorontsov, E.; Ståhlman, M.; Nuñez-Durán, E.; Borén, J.; Marschall, H.-U.; et al. Lipid droplet-associated kinase STK25 regulates peroxisomal activity and metabolic stress response in steatotic liver. *J. Chem. Inf. Model.* **2020**, *53*, 45–50. [CrossRef]
239. Sharma, R.S.; Harrison, D.J.; Kisielewski, D.; Cassidy, D.M.; McNeilly, A.D.; Gallagher, J.R.; Walsh, S.V.; Honda, T.; McCrimmon, R.J.; Dinkova-Kostova, A.T.; et al. Experimental nonalcoholic steatohepatitis and liver fibrosis are ameliorated by pharmacologic activation of Nrf2 (NF-E2 p45-related factor 2). *Cell. Mol. Gastroenterol. Hepatol.* **2018**, *5*, 367–398. [CrossRef]

240. Solano-Urrusquieta, A.; Morales-González, J.A.; Castro-Narro, G.E.; Cerda-Reyes, E.; Flores-Rangel, P.D.; Fierros-Oceguera, R. Nrf-2 and nonalcoholic fatty liver disease. *Ann. Hepatol.* **2020**. [CrossRef]

241. Meakin, P.J.; Chowdhry, S.; Sharma, R.S.; Ashford, F.B.; Walsh, S.V.; McCrimmon, R.J.; Dinkova-Kostova, A.T.; Dillon, J.F.; Hayes, J.D.; Ashford, M.L.J. Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes but not with I. *Mol. Cell. Biol.* **2014**, *34*, 3305–3320. [CrossRef] [PubMed]

242. Chowdhry, S.; Nazmy, M.H.; Meakin, P.J.; Dinkova-Kostova, A.T.; Walsh, S.V.; Tsujita, T.; Dillon, J.F.; Ashford, M.L.J.; Hayes, J.D. Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. *Free Radic. Biol. Med.* **2010**, *48*, 357–371. [CrossRef] [PubMed]

243. Wang, C.; Cui, Y.; Li, C.; Zhang, Y.; Xu, S.; Li, X.; Li, H.; Zhang, X. Nrf2 deletion causes "benign" simple steatosis to develop into nonalcoholic steatohepatitis in mice fed a high-fat diet. *Lipids Health Dis.* **2013**, *12*, 1. [CrossRef] [PubMed]

244. Teimouri, M.; Hosseini, H.; Shabani, M.; Koushki, M.; Noorbakhsh, F.; Meshkani, R. Inhibiting miR-27a and miR-142-5p attenuate nonalcoholic fatty liver disease by regulating Nrf2 signaling pathway. *IUBMB Life* **2020**, *72*, 361–372. [CrossRef] [PubMed]

245. Yu, H.T.; Fu, X.Y.; Liang, B.; Wang, S.; Liu, J.K.; Wang, S.R.; Feng, Z.H. Oxidative damage of mitochondrial respiratory chain in different organs of a rat model of diet-induced obesity. *Eur. J. Nutr.* **2018**, *57*, 1957–1967. [CrossRef]

246. García-Ruiz, I.; Fernández-Moreira, D.; Solís-Muñoz, P.; Rodríguez-Juan, C.; Díaz-Sanjuán, T.; Muñoz-Yagüe, T.; Solís-Herruzo, J.A. Mitochondrial complex i subunits are decreased in murine nonalcoholic fatty liver disease: Implication of peroxynitrite. *J. Proteome Res.* **2010**, *9*, 2450–2459. [CrossRef]

247. Nassir, F.; Ibdah, J.A. Sirtuins and nonalcoholic fatty liver disease. *World J. Gastroenterol.* **2016**, *22*, 10084–10092. [CrossRef]

248. Satapati, S.; Browning, J.D.; Shawn, C.; Satapati, S.; Kucejova, B.; Duarte, J.A.G.; Fletcher, J.A.; Reynolds, L.; Sunny, N.E.; He, T.; et al. Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver. *J. Clin. Investig.* **2016**, *125*, 4447–4462. [CrossRef]

249. Krishnasamy, Y.; Gooz, M.; Li, L.; Lemasters, J.J.; Zhong, Z. 512-Role of mitochondrial depolarization and disrupted mitochondrial homeostasis in non-alcoholic steatohepatitis and fibrosis. *Gastroenterology* **2018**, *154*, 1095–1096. [CrossRef]

250. Win, S.; Than, T.A.; Win, M.M.R.; Aghajan, M.; Kaplowitz, N. JNK mediates mouse liver injury through a novel Sab (SH3BP5) dependent pathway leading to inactivation of intramitochondrial src sanda. *Hepatology* **2017**, *176*, 139–148. [CrossRef]

251. Win, S.; Than, T.A.; Zhang, J.; Oo, C.; Win, R.W.M.; Kaplowitz, N. New insights into the role and mechanism of c-Jun-N-terminal kinase signaling in the pathobiology of liver diseases. *Hepatology* **2018**, *176*, 139–148. [CrossRef] [PubMed]

252. Hinchy, E.C.; Gruszczyk, A.V.; Willows, R.; Navaratnam, N.; Hall, A.R.; Bates, G.; Bright, T.P.; Krieg, T.; Carling, D.; Murphy, M.P. Mitochondria-derived ROS activate AMP-activated protein kinase (AMPK) indirectly. *J. Biol. Chem.* **2018**, *293*, 17208–17217. [CrossRef] [PubMed]

253. Mansouri, A.; Gattolliat, C.H.; Asselah, T. Mitochondrial dysfunction and signaling in chronic liver diseases. *Gastroenterology* **2018**, *155*, 629–647. [CrossRef] [PubMed]

254. Kim, M.H.; Seong, J.B.; Huh, J.W.; Bae, Y.C.; Lee, H.S.; Lee, D.S. Peroxiredoxin 5 ameliorates obesity-induced non-alcoholic fatty liver disease through the regulation of oxidative stress and AMP-activated protein kinase signaling. *Redox Biol.* **2020**, *28*, 101315. [CrossRef] [PubMed]

255. Zhao, P.; Sun, X.; Chaggan, C.; Liao, Z.; Wong, K.I.; He, F.; Singh, S.; Loomba, R.; Karin, M.; Witztum, J.L.; et al. An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis. *Science* **2020**, *367*, 652–660. [CrossRef] [PubMed]

256. Simões, I.C.M.; Fontes, A.; Pinton, P.; Zischka, H.; Wieckowski, M.R. Mitochondria in non-alcoholic fatty liver disease. *Int. J. Biochem. Cell Biol.* **2018**, *95*, 93–99. [CrossRef]
257. Masarone, M.; Rosato, V.; Dallio, M.; Gravina, A.G.; Aglitti, A.; Loguercio, C.; Federico, A.; Persico, M. Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease. *Oxid. Med. Cell. Longev.* **2018**, *2018*. [CrossRef]

258. Kim, J.Y.; Garcia-Carbonell, R.; Yamachika, S.; Zhao, P.; Dhar, D.; Loomba, R.; Kaufman, R.J.; Saltiel, A.R.; Karin, M. ER stress drives lipogenesis and steatohepatitis via caspase-2 activation of S1P. *Cell* **2018**, *175*, 133–145. [CrossRef]

259. Greene, M.W.; Burrington, C.M.; Ruhoff, M.S.; Johnson, A.K.; Chongkrairatanakul, T.; Kangwanpornsiri, A. PKCδ is activated in a dietary model of steatohepatitis and regulates endoplasmic reticulum stress and cell death. *J. Biol. Chem.* **2010**, *285*, 42115–42129. [CrossRef]

260. Lai, S.; Li, Y.; Kuang, Y.; Cui, H.; Yang, Y.; Sun, W.; Liu, K.; Chen, D.; Yan, Q.; Wen, L. PKCδ silencing alleviates saturated fatty acid induced ER stress by enhancing SERCA activity. *Biosci. Rep.* **2017**, *37*, 1–10. [CrossRef]

261. Zhang, B.; Li, M.; Zou, Y.; Guo, H.; Zhang, B.; Xia, C.; Zhang, H.; Yang, W.; Xu, C. NFκB/Orai1 facilitates endoplasmic reticulum stress by oxidative stress in the pathogenesis of non-alcoholic fatty liver disease. *Front. Cell Dev. Biol.* **2019**, *7*, 1–13. [CrossRef]

262. Luo, L.; Jiang, W.; Liu, H.; Bu, J.; Tang, P.; Du, C.; Xu, Z.; Luo, H.; Liu, B.; Xiao, B.; et al. De-silencing Grb10 contributes to acute ER stress-induced steatosis in mouse liver. *J. Mol. Endocrinol.* **2018**, *60*, 285–297. [CrossRef] [PubMed]

263. Ipsen, D.H.; Lykkesfeldt, J.; Tveden-Nyborg, P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. *Cell. Mol. Life Sci.* **2018**, *75*, 3313–3327. [CrossRef] [PubMed]

264. Huang, B.; Bao, J.; Cao, Y.R.; Gao, H.F.; Jin, Y. Cytochrome P450 1A1 (CYP1A1) catalyzes lipid peroxidation of oleic acid-induced HepG2 cells. *Biochemistry* **2018**, *83*, 595–602. [CrossRef] [PubMed]

265. Gao, H.; Cao, Y.; Xia, H.; Zhu, X.; Jin, Y. CYP4A11 is involved in the development of nonalcoholic fatty liver disease via ROS-induced lipid peroxidation and inflammation. *Int. J. Mol. Med.* **2020**, *45*, 1121–1129. [CrossRef]

266. Abdelmeeged, M.A.; Ha, S.-K.; Choi, Y.; Akbar, M.; Song, B.-J. Role of CYP2E1 in mitochondrial dysfunction and hepatic injury by alcohol and Non-alcoholic substances. *Curr. Mol. Pharmacol.* **2017**, *10*, 207–225. [CrossRef]

267. Huang, Y.S.; Chang, C.H.; Lin, T.L.; Perng, C.L. Genetic variations of superoxide dismutase 2 and cytochrome P450 2E1 in non-alcoholic steatohepatitis. *Liver Int.* **2014**, *34*, 931–936. [CrossRef]

268. Chen, G.; Renfan, X.; Zhang, S.; Wang, Y.; Wang, P.; Edin, M.L.; Zeldin, D.C.; Wang, D.W. CYP2J2 overexpression attenuates nonalcoholic fatty liver disease induced by high-fat diet in mice. *Am. J. Physiol. Endocrinol. Metab.* **2015**, *308*, E97–E110. [CrossRef]

269. Rabelo, F.; Stefano, J.T.; Cavaleiro, A.M.; Lima, R.V.C.; de Campos Mazo, D.F.; Carrilho, F.J.; Correa-Giannella, M.L.; Oliveira, C.P. Association between the CYBA and NOX4 genes of NADPH oxidase and its relationship with metabolic syndrome in non-alcoholic fatty liver disease in Brazilian population. *Hepatobiliary Pancreat. Dis. Int.* **2018**, *17*, 330–335. [CrossRef]

270. García-Ruiz, I.; Solís-Muñoz, P.; Fernández-Moreira, D.; Grau, M.; Muñoz-Yagüe, T.; Solís-Herruzo, J.A. NADPH oxidase is implicated in the pathogenesis of oxidative phosphorylation dysfunction in mice fed a high-fat diet. *Sci. Rep.* **2016**, *6*, 1–13. [CrossRef]

271. Loffredo, L.; Zicari, A.M.; Perri, L.; Carnevale, R.; Nocella, C.; Angelico, F.; Del Ben, M.; Mosca, A.; Zaffina, S.; Panera, N.; et al. Does Nox2 overactivate in children with nonalcoholic fatty liver disease. *Antioxid. Redox Signal.* **2019**, *30*, 1325–1330. [CrossRef] [PubMed]

272. Del Ben, M.; Polimeni, L.; Carnevale, R.; Bartimoccia, S.; Nocella, C.; Baratta, F.; Loffredo, L.; Pignatelli, P.; Violi, F.; Angelico, F. NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease. *BMC Gastroenterol.* **2014**, *14*, 1–8. [CrossRef] [PubMed]

273. García-Ruiz, I.; Solís-Muñoz, P.; Fernández-Moreira, D.; Grau, M.; Colina, F.; Muñoz-Yagüe, T.; Solís-Herruzo, J.A. High-fat diet decreases activity of the oxidative phosphorylation complexes and causes nonalcoholic steatohepatitis in mice. *DMM Dis. Model. Mech.* **2014**, *7*, 1287–1296. [CrossRef] [PubMed]

274. Long, Z.; Cao, M.; Su, S.; Wu, G.; Meng, F.; Wu, H.; Liu, J.; Yu, W.; Atabai, K.; Wang, X. Inhibition of hepatocyte nuclear factor 1b induces hepatic steatosis through DPP4/NOX1-mediated regulation of superoxide. *Free Radic. Biol. Med.* **2017**, *113*, 71–83. [CrossRef]
275. Matsumoto, M.; Zhang, J.; Zhang, X.; Liu, J.; Jiang, J.X.; Yamaguchi, K.; Taruno, A.; Katsuyama, M.; Iwata, K.; Ibi, M.; et al. The NOX1 isoform of NADPH oxidase is involved in dysfunction of liver sinusoids in nonalcoholic fatty liver disease. *Free Radic. Biol. Med.* **2018**, *115*, 412–420. [CrossRef]

276. Joy, A.B.; Jiang, X.; Sasaki, Y.; Chao, T.-I.; Kiss, Z.; Chen, X.; Tian, J.; Katsuyama, M.; Yabe-Nishimura, C.; Xi, Y.; et al. Hepatocyte NADPH oxidase 4 regulates stress signaling, fibrosis, and insulin sensitivity during development of steatohepatitis in mice. *Gastroenterology* **2015**, *149*, 468–480. [CrossRef]

277. Schnabl, B.; Choi, Y.H.; Olsen, J.C.; Hagedorn, C.H.; Brenner, D.A. Generated by ectopic telomerase expression. *Lab. Investig.* **2002**, *82*, 323–333. [CrossRef] [PubMed]

278. Sun, J.S.X.; Seidman, P.Z.; Christopher, K.S.T.; Glass, J.L.W. Neutralization of oxidized phospholipids article neutralization of oxidized phospholipids ameliorates non-alcoholic steatohepatitis. *Cell Metab.* **2020**, 1–18. [CrossRef]

279. Mendel, I.; Yacov, N.; Shoham, A.; Ishai, E.; Breitbart, E. Treatment with oxidized phospholipids directly inhibits nonalcoholic steatohepatitis and liver fibrosis without affecting steatosis. *Dig. Dis. Sci.* **2016**, *61*, 2545–2553. [CrossRef]

280. Valenti, L.; Rametta, R.; Dongiovanni, P.; Motta, B.M.; Canavesi, E.; Pelusi, S.; Pulixi, E.A.; Fracanzani, A.L.; Fargion, S. The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease. *PLoS ONE* **2012**, *7*, e48804. [CrossRef]

281. Kowdley, K.V.; Belt, P.; Wilson, L.A.; Yeh, M.M.; Neuschwander-Tetri, B.A.; Chalasani, N.; Sanyal, A.J.; Nelson, J.E. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. *Hepatology* **2012**, *55*, 77–85. [CrossRef] [PubMed]

282. Mehta, K.J.; Farnaud, S.J.; Sharp, P.A. Iron and liver fibrosis: Mechanistic and clinical aspects. *World J. Gastroenterol.* **2019**, *25*, 521–538. [CrossRef] [PubMed]

283. Claus, S.P.; Tsang, T.M.; Wang, Y.; Cloarec, O.; Skordi, E.; Martin, F.P.; Rezzi, S.; Ross, A.; Kochhar, S.; Holmes, E.; et al. Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes. *Mol. Syst. Biol.* **2008**, *4*, 1–14. [CrossRef] [PubMed]

284. Mardinoglu, A.; Shoaie, S.; Bergentall, M.; Ghaffari, P.; Zhang, C.; Larsson, E.; Bäckhed, F.; Nielsen, J. The gut microbiota modulates host amino acid and glutathione metabolism in mice. *Mol. Syst. Biol.* **2015**, *11*, 834. [CrossRef] [PubMed]

285. Saeedi, B.J.; Liu, K.H.; Owens, J.A.; Hunter-Chang, S.; Camacho, M.C.; Eboka, R.U.; Chandrasekharan, B.; Baker, N.F.; Darby, T.M.; Robinson, B.S.; et al. Gut-resident lactobacilli activate hepatic Nrf2 and protect against oxidative liver injury. *Cell Metab.* **2020**, *31*, 956–968.e5. [CrossRef] [PubMed]

286. Meng, X.; Li, S.; Li, Y.; Gan, R.Y.; Li, H. Bin Gut microbiota's relationship with liver disease and role in hepatoprotection by dietary natural products and probiotics. *Nutrients* **2018**, *10*, 1457. [CrossRef] [PubMed]

287. Ji, Y.; Yin, Y.; Sun, L.; Zhang, W. The molecular and mechanistic insights based on gut-liver axis: Nutritional target for non-alcoholic fatty liver disease (NAFLD) improvement. *Int. J. Mol. Sci.* **2020**, *21*, 3066. [CrossRef]

288. Wang, B.; Jiang, X.; Cao, M.; Ge, J.; Bao, Q.; Tang, L.; Chen, Y.; Li, L. Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease. *Sci. Rep.* **2016**, *6*, 1–11. [CrossRef]

289. Boursier, J.; Rawls, J.F.; Diehl, A.M. Obese humans with nonalcoholic fatty liver disease display alterations in fecal microbiota and volatile organic compounds. *Clin. Gastroenterol. Hepatol.* **2013**, *11*, 876–878. [CrossRef]

290. Machado, M.V.; Ravasco, P.; Jesus, L.; Marques-Vidal, P.; Oliveira, C.R.; Proença, T.; Baldeiras, I.; Camilo, M.E.; Cortez-Pinto, H. Blood oxidative stress markers in non-alcoholic steatohepatitis and how it correlates with diet. *Scand. J. Gastroenterol.* **2008**, *43*, 95–102. [CrossRef]

291. Yamaguchi, K.; Yang, L.; McCall, S.; Huang, J.; Xing, X.Y.; Pandey, S.K.; Bhanot, S.; Monia, B.P.; Li, Y.X.; Diehl, A.M. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. *Hepatology* **2007**, *45*, 1366–1374. [CrossRef] [PubMed]

292. Puri, P.; Baillie, R.A.; Wiest, M.M.; Mirshahi, F.; Choudhury, J.; Cheung, O.; Sargeant, C.; Contos, M.J.; Sanyal, A.J. A lipidomic analysis of nonalcoholic fatty liver disease. *Hepatology* **2007**, *46*, 1081–1090. [CrossRef] [PubMed]

293. Sengupta, A.; Ghosh, M. Comparison of native and capric acid-enriched mustard oil effects on oxidative stress and antioxidant protection in rats. *Br. J. Nutr.* **2012**, *107*, 845–849. [CrossRef] [PubMed]

294. Sengupta, A.; Ghosh, M.; Bhattacharyya, D.K. Antioxidative effect of rice bran oil and medium chain fatty acid rich rice bran oil in arsenite induced oxidative stress in rats. *J. Oleo Sci.* **2014**, *63*, 1117–1124. [CrossRef]
295. Wang, D.; Wei, Y.; Pagliassotti, M.J. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. *Endocrinology* **2006**, *147*, 943-951. [CrossRef]

296. Nakamura, H.; Tsujiguchi, H.; Kambayashi, Y.; Hara, A.; Miyagi, S.; Yamada, Y.; Nguyen, T.T.; Shimizu, Y.; Hori, D.; Nakamura, H. Relationship between saturated fatty acid intake and hypertension and oxidative stress. *Nutrition* **2019**, *61*, 8-15. [CrossRef]

297. Ghazali, R.; Mehta, K.J.; Bligh, S.W.A.; Tewfik, I.; Clemens, D.; Patel, V.B. High omega arachidonic acid/docosahexaenoic acid ratio induces mitochondrial dysfunction and altered lipid metabolism in human hepatoma cells. *World J. Hepatol.* **2020**, *12*, 84-98. [CrossRef]

298. Jeyapal, S.; Kona, S.R.; Mullapudi, S.V.; Putcha, U.K.; Gurumurthy, P.; Ibrahim, A. Substitution of linoleic acid with α-linolenic acid or long chain n-3 polyunsaturated fatty acid prevents Western diet induced nonalcoholic steatohepatitis. *Sci. Rep.* **2018**, *8*, 1-14. [CrossRef]

299. García-Ruiz, C.; Fernández-Checa, J.C. Mitochondrial oxidative stress and antioxidants balance in fatty liver disease. *Hepatol. Commun.* **2018**, *2*, 1425-1439. [CrossRef]

300. Domínguez-Pérez, M.; Simoni-Nieves, A.; Rosales, P.; Nuño-Lámbarri, N.; Rosas-Lemus, M.; Souza, V.; Miranda, R.U.; Bucio, L.; Uribe Carvajal, S.; Marquardt, J.U.; et al. Cholesterol burden in the liver induces mitochondrial dynamic changes and resistance to apoptosis. *J. Cell. Physiol.* **2019**, *234*, 7213-7223. [CrossRef]

301. Püschel, G.P.; Henkel, J. Dietary cholesterol does not break your heart but kills your liver. *Porto Biomed.* *J.* **2018**, *3*, e12. [CrossRef] [PubMed]

302. Savard, G.; Tartaglione, E.; Kuver, R.; Haigh, W.; Farrell, G.; Subramanian, S.; Chait, A.; Yeh, M.; Quinn, L.; Ioannou, G. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis christopher. *Hepatology* **2013**, *57*, 81-92. [CrossRef] [PubMed]

303. Bellanti, F.; Villani, R.; Tamborra, R.; Blonda, M.; Iannelli, G.; di Bello, G.; Facciorusso, A.; Poli, G.; Iuliano, L.; Avolio, C.; et al. Synergistic interaction of fatty acids and oxysterols impairs mitochondrial function and limits liver adaptation during nafld progression. *Redox Biol.* **2018**, *15*, 86-96. [CrossRef] [PubMed]

304. Henkel, J.; Coleman, C.D.; Schraplau, A.; Jöhrens, K.; Weber, D.; Castro, J.P.; Hugo, M.; Schulz, T.J.; Krämer, S.; Schürmann, A.; et al. Induction of steatohepatitis (NASH) with insulin resistance in wild-type B6 mice by a western-type diet containing soybean oil and cholesterol. *Mol. Med.* **2017**, *23*, 70-82. [CrossRef] [PubMed]

305. Kephart, W.C.; Mumford, P.W.; Mao, X.; Romero, M.A.; Hyatt, H.W.; Zhang, Y.; Mobley, C.B.; Quindry, J.C.; Young, K.C.; Beck, D.T.; et al. The 1-week and 8-month effects of a ketogenic diet or ketone salt supplementation on multi-organ markers of oxidative stress and mitochondrial function in rats. *Nutrients* **2017**, *9*, 1019. [CrossRef] [PubMed]

306. Lanaspa, M.A.; Sanchez-Lozada, L.G.; Choi, Y.J.; Cicerchi, C.; Kanbay, M.; Roncal-Jimenez, C.A.; Ishimoto, T.; Li, N.; Marek, G.; Duranay, M.; et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: Potential role in fructose-dependent and -independent fatty liver. *J. Biol. Chem.* **2012**, *287*, 40732-40744. [CrossRef]

307. Cho, Y.E.; Kim, D.K.; Seo, W.; Gao, B.; Yoo, S.H.; Song, B.J. Fructose promotes leaky gut, endotoxemia, and liver fibrosis through ethanol-inducible cytochrome P450-2E1-mediated oxidative and nitrative stress. *Hepatology* **2019**, *1-16*. [CrossRef]

308. Castro, M.C.; Francini, F.; Schinella, G.; Caldiz, C.I.; Zubiría, M.G.; Gagliardino, J.J.; Massa, M.L. Apocynin administration prevents the changes induced by a fructose-rich diet on rat liver metabolism and the antioxidant system. *Clin. Sci.* **2012**, *123*, 681-692. [CrossRef]

309. Francini, F.; Castro, M.C.; Schinella, G.; García, M.E.; Maiztegui, B.; Raschia, M.A.; Gagliardino, J.J.; Massa, M.L. Changes induced by a fructose-rich diet on hepatic metabolism and the antioxidant system. *Life Sci.* **2010**, *86*, 965-971. [CrossRef]

310. Castro, M.C.; Massa, M.L.; Arbeláez, L.G.; Schinella, G.; Gagliardino, J.J.; Francini, F. Fructose-induced inflammation, insulin resistance and oxidative stress: A liver pathological triad effectively disrupted by lipoic acid. *Life Sci.* **2015**, *137*, 1-6. [CrossRef]

311. Oliveira, L.S.; Caetano, B.; Miranda, R.A.; Souza, A.F.P.; Cordeiro, A.; Woyames, J.; Andrade, C.B.V.; Atella, G.C.; Takiya, C.M.; Fortunato, R.S.; et al. Differentiated hepatic response to fructose intake during adolescence reveals the increased susceptibility to non-alcoholic fatty liver disease of maternal high-fat diet male rat offspring. *Mol. Nutr. Food Res.* **2020**, *64*, 1-10. [CrossRef] [PubMed]
312. Fujita, N.; Miyachi, H.; Tanaka, H.; Takeo, M.; Nakagawa, N.; Kobayashi, Y.; Iwasa, M.; Watanabe, S.; Takei, Y. Iron overload is associated with hepatic oxidative damage to DNA in nonalcoholic steatohepatitis. *Cancer Epidemiol. Biomark. Prev.* **2009**, *18*, 424–432. [CrossRef] [PubMed]

313. Atarashi, M.; Izawa, T.; Miyagi, R.; Ohji, S.; Hashimoto, A.; Kuwamura, M.; Yamate, J. Dietary iron supplementation alters hepatic inflammation in a rat model of nonalcoholic steatohepatitis. *Nutrients* **2018**, *10*, 175. [CrossRef] [PubMed]

314. Handa, P.; Morgan-Stevenson, V.; Maliken, B.D.; Nelson, J.E.; Washington, S.; Westerman, M.; Yeh, M.M.; Kowdley, K.V. Iron overload results in hepatic oxidative stress, immune cell activation, and hepatocellular ballooning injury, leading to nonalcoholic steatohepatitis in genetically obese mice. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2016**, *310*, G117–G127. [CrossRef] [PubMed]

315. Protchenko, O.; Baratz, E.; Jadhav, S.; Li, F.; Shakoury-Elizeh, M.; Gavrilova, O.; Ghosh, M.C.; Cox, J.E.; Maschek, J.A.; Tyurin, V.A.; et al. Iron chaperone PCBP1 protects murine liver from lipid peroxidation and steatosis. *Hepatology* **2020**. [CrossRef]

316. Hagström, H.; Nasr, P.; Bottai, M.; Ekstedt, M.; Kechagias, S.; Hultcrantz, R.; Stål, P. Elevated serum ferritin is associated with increased mortality in non-alcoholic fatty liver disease after 16 years of follow-up. *Liver Int.* **2016**, *36*, 1688–1695. [CrossRef]

317. Kim, H.B.; Lee, H.S.; Lee, Y.J. Association of serum ferritin levels with non-alcoholic fatty liver disease in postmenopausal women. *Climacteric* **2018**, *21*, 509–514. [CrossRef]

318. Ahmad, M.I.; Ijaz, M.U.; ul Haq, I.; Li, C. The role of meat protein in generation of oxidative stress and pathophysiology of metabolic syndromes. *Food Sci. Anim. Resour.* **2020**, *40*, 1–10. [CrossRef]

319. Parker, H.M.; Johnson, N.A.; Burdon, C.A.; Cohn, J.S.; O’Connor, H.T.; George, J. Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis. *J. Hepatol.* **2012**, *56*, 944–951. [CrossRef]

320. Guo, X.F.; Yang, B.; Tang, J.; Li, D. Fatty acid and non-alcoholic fatty liver disease: Meta-analyses of case-control and randomized controlled trials. *Clin. Nutr.* **2018**, *37*, 113–122. [CrossRef]

321. Musa-Veloso, K.; Venditti, C.; Lee, H.Y.; Darch, M.; Floyd, S.; West, S.; Simon, R. Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease. *Nutr. Rev.* **2018**, *76*, 581–602. [CrossRef] [PubMed]

322. Chen, L.-H.; Wang, Y.-F.; Xu, Q.-H.; Chen, S.S. Omega-3 fatty acids as a treatment for non-alcoholic fatty liver disease in children: A systematic review and meta-analysis of randomized controlled trials. *Clin. Nutr.* **2018**, *37*, 516–521. [CrossRef] [PubMed]

323. Yang, J.; Fernández-Galilea, M.; Martínez-Fernández, L.; González-Muniesa, P.; Pérez-Chávez, A.; Martínez, J.A.; Moreno-Aliaga, M.J. Oxidative stress and non-alcoholic fatty liver disease: Effects of omega-3 fatty acid supplementation. *Nutrients* **2019**, *11*, 872. [CrossRef] [PubMed]

324. Scorletti, E.; Byrne, C.D. Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action. *Mol. Asp. Med.* **2018**, *64*, 135–146. [CrossRef]

325. Valenzuela, R.; Videla, L.A. Impact of the co-administration of n-3 fatty acids and olive oil components in preclinical nonalcoholic fatty liver disease models: A mechanistic view. *Nutrients* **2020**, *12*, 499. [CrossRef] [PubMed]

326. Valenzuela, R.; Espinosa, A.; González-Mañán, D.; D’Espessailles, A.; Fernández, V.; Videla, L.A.; Tapia, G. N-3 Long-Chain Polyunsaturated Fatty Acid Supplementation Significantly Reduces Liver Oxidative Stress in High Fat Induced Steatosis. *PLoS ONE* **2012**, *7*, e46400. [CrossRef]

327. Jump, D.B.; Depner, C.M.; Tripathy, S.; Lytle, K.A. Potential for dietary ω-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer. *Adv. Nutr.* **2015**, *6*, 694–702. [CrossRef]

328. Gao, L.; Wang, J.; Sekhar, K.R.; Yin, H.; Yared, N.F.; Schneider, S.N.; Sasi, S.; Dalton, T.P.; Anderson, M.E.; Chan, J.Y.; et al. Novel n-3 fatty acid oxidation products activate Nrf2 by destabilizing the association between Keap1 and Cullin3. *J. Biol. Chem.* **2007**, *282*, 2529–2537. [CrossRef]

329. Depner, C.; Philbrick, K.; Jump, D. Docosahexaenoic Acid Attenuates Hepatic Inflammation, Oxidative Stress, and Fibrosis without Decreasing Hepatosteatosis in a Ldlr-/- Mouse Model of Western Diet. *J. Nutr.* **2013**, *143*, 315–323. [CrossRef]

330. Soto-Alarcon, S.A.; Valenzuela, R.; Valenzuela, A.; Videla, L.A. Liver protective effects of extra virgin olive oil: Interaction between its chemical composition and the cell-signaling pathways involved in protection. *Endocr. Metab. Immune Disord. Drug Targets* **2017**, *18*, 75–84. [CrossRef]
331. Rincón-Cervera, M.A.; Valenzuela, R.; Hernandez-Rodas, M.C.; Marambio, M.; Espinosa, A.; Mayer, S.; Romero, N.; Barrera M Sc, C.; Valenzuela, A.; Videla, L.A. Supplementation with antioxidant-rich extra virgin olive oil prevents hepatic oxidative stress and reduction of desaturation capacity in mice fed a high-fat diet: Effects on fatty acid composition in liver and extrahepatic tissues. *Nutrition* **2016**, *32*, 1254–1267. [CrossRef] [PubMed]

332. Chakravarthy, M.V.; Waddell, T.; Banerjee, R.; Guess, N. Nutrition and nonalcoholic fatty liver disease: Current perspectives. *Gastroenterol. Clin. N. Am.* **2020**, *49*, 63–94. [CrossRef] [PubMed]

333. Mardinoglu, A.; Bjornson, E.; Zhang, C.; Klevstig, M.; Söderlund, S.; Ståhlman, M.; Adiels, M.; Hakkarainen, A.; Lundbom, N.; Kilicarslan, M.; et al. Personal model-assisted identification of NAD + and glutathione metabolism as intervention target in NAFLD. *Mol. Syst. Biol.* **2017**, *13*, 916. [CrossRef] [PubMed]

334. Aissa, A.F.; Tryndyak, V.; de Conti, A.; Melnyk, S.; Gomes, T.D.U.H.; Bianchi, M.L.P.; James, S.J.; Beland, F.A.; Antunes, L.M.G.; Pogribny, I.P. Effect of methionine-deficient and methionine-supplemented diets on the hepatic one-carbon and lipid metabolism in mice. *Mol. Nutr. Food Res.* **2014**, *58*, 1502–1512. [CrossRef]

335. Anstee, Q.; Goldin, R.D. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. *Int. J. Exp. Path* **2006**, *87*, 1–16. [CrossRef]

336. Larter, C.Z.; Yeh, M.M. Animal models of NASH: Getting both pathology and metabolic context right. *J. Gastroenterol. Hepatol.* **2008**, *23*, 1635–1648. [CrossRef]

337. Rinella, M.E.; Green, R.M. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. *J. Hepatol.* **2004**, *40*, 47–51. [CrossRef]

338. Drake, A.J.; Lyall, M.J.; Cartier, J.; Richards, J.A.; Cobice, D.; Thomson, J.P.; Meehan, R.R.; Anderton, S.M. Methyl donor deficient diets cause distinct alterations in lipid metabolism but are poorly representative of human NAFLD [version 1; referees: 2 approved]. *Wellcome Open Res.* **2017**, *2*, 1–19. [CrossRef]

339. Murakami, S.; Ono, A.; Kawasaki, A.; Takenaga, T.; Ito, T. Taurine attenuates the development of hepatic steatosis through the inhibition of oxidative stress in a model of nonalcoholic fatty liver disease in vivo and in vitro. *Amino Acids* **2018**, *50*, 1279–1288. [CrossRef]

340. Shenkin, A. The key role of micronutrients. *Clin. Nutr.* **2006**, *25*, 1–13. [CrossRef]

341. Chen, G.; Ni, Y.; Nagata, N.; Xu, L.; Ota, T. Micronutrient antioxidants and nonalcoholic fatty liver disease. *Int. J. Mol. Sci.* **2016**, *17*, 1379. [CrossRef] [PubMed]

342. Karatayli, E.; Stokes, C.S.; Lammert, F. Vitamin D in preclinical models of fatty liver disease. *Anticancer Res.* **2020**, *40*, 527–534. [CrossRef] [PubMed]

343. Eliades, M.; Spyrou, E.; Agrawal, N.; Lazo, M.; Brancati, F.L.; Potter, J.J.; Koteish, A.A.; Clark, J.M.; Guallar, E.; Hernaez, R. Meta-analysis: Vitamin D and non-alcoholic fatty liver disease. *Aliment. Pharmacol. Ther.* **2013**, *38*, 246–254. [CrossRef]

344. Sato, K.; Gosho, M.; Yamamoto, T.; Kobayashi, Y.; Ishii, N.; Ohashi, T.; Nakade, Y.; Ito, K.; Fukuzawa, Y.; Yoneda, M. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials. *Nutrition* **2015**, *31*, 923–930. [CrossRef] [PubMed]

345. Liu, S.; Liu, Y.; Wan, B.; Zhang, H.; Wu, S.; Zhu, Z.; Lin, Y.; Wang, M.; Zhang, N.; Lin, S.; et al. Association between vitamin D status and non-alcoholic fatty liver disease: A population-based study. *J. Nutr. Sci. Vitaminol.* **2019**, *65*, 303–308. [CrossRef] [PubMed]

346. Sanyal, A.J.; Chalasani, N.; Kowdley, K.; McCullough, A.; Diehl, A.; Bass, N.; Neuschwander-Tetri, B.; Lavine, J.; Tonascia, J.; Unalp, A.; et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *N. Engl. J. Med.* **2010**, *362*, 1675–1685. [CrossRef] [PubMed]

347. Nagashimada, M.; Ota, T. Role of vitamin E in nonalcoholic fatty liver disease. *IUBMB Life* **2019**, *71*, 516–522. [CrossRef] [PubMed]

348. Fougerat, A.; Montagner, A.; Loiseau, N.; Guillou, H.; Wahli, W. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. *Cells* **2020**, *9*, 1638. [CrossRef] [PubMed]

349. Salomone, F.; Godos, J.; Zelber-Sagi, S. Natural antioxidants for non-alcoholic fatty liver disease: Molecular targets and clinical perspectives. *Liver Int.* **2016**, *36*, 5–20. [CrossRef] [PubMed]

350. Rodriguez-Ramiro, I.; Vauzour, D.; Minihane, A.M. Polyphenols and non-alcoholic fatty liver disease: Impact and mechanisms. *Proc. Nutr. Soc.* **2016**, *75*, 47–60. [CrossRef] [PubMed]
351. Elvira-Torales, L.I.; García-Alonso, J.; Periago-Castón, M.J. Nutritional importance of carotenoids and their effect on liver health: A review. *Antioxidants* **2019**, *8*, 229. [CrossRef] [PubMed]

352. Hill, C.; Guarner, F.; Reid, G.; Gibson, G.R.; Merenstein, D.J.; Pot, B.; Morelli, L.; Canani, R.B.; Flint, H.J.; Salminen, S.; et al. Expert consensus document: The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat. Rev. Gastroenterol. Hepatol.* **2014**, *11*, 506–514. [CrossRef]

353. Ritze, Y.; Bárdos, G.; Claus, A.; Ehrmann, V.; Bergheim, I.; Schwiertz, A.; Bischoff, S.C. Lactobacillus rhamnosus GG Protects against non-alcoholic fatty liver disease in mice. *PLoS ONE* **2014**, *9*, e80169. [CrossRef] [PubMed]

354. Jang, H.R.; Park, H.J.; Kang, D.; Chung, H.; Nam, M.H.; Lee, Y.; Park, J.H.; Lee, H.Y. A protective mechanism of probiotic Lactobacillus against hepatic steatosis via reducing host intestinal fatty acid absorption. *Exp. Mol. Med.* **2019**, *51*. [CrossRef] [PubMed]

355. Ling, X.; Linglong, P.; Weixia, D.; Hong, W. Protective effects of bifidobacterium on intestinal barrier function in LPS-induced enterocyte barrier injury of Caco-2 monolayers and in a rat NEC model. *PLoS ONE* **2016**, *11*, e0161635. [CrossRef]

356. Liver, F.; Nafld, D. Chitosan Oligosaccharide Ameliorates Nonalcoholic. *Mar. Drugs* **2019**, *17*, 391. [CrossRef]

357. Pan, L.; Farouk, M.H.; Qin, G.; Zhao, Y.; Bao, N. The influences of soybean agglutinin and functional oligosaccharides on the intestinal tract of monogastric animals. *Int. J. Mol. Sci.* **2018**, *19*, 554. [CrossRef]

358. Kumar, J.; Rani, K.; Datt, C. Molecular link between dietary fibre, gut microbiota and health. *Mol. Biol. Rep.* **2020**, *47*, 6229–6237. [CrossRef]

359. Zhou, D.; Fan, J.G. Microbial metabolites in non-alcoholic fatty liver disease. *World J. Gastroenterol.* **2019**, *25*, 2019–2028. [CrossRef]

360. Sellmann, C.; Baumann, A.; Brandt, A.; Jin, C.J.; Nier, A.; Bergheim, I. Oral supplementation of glutamine attenuates the progression of nonalcoholic steatohepatitis in C57BL/6J mice. *J. Nutr.* **2017**, *147*, 2041–2049. [CrossRef]

361. Clugston, R.D. Carotenoids and fatty liver disease: Current knowledge and research gaps. *Biochim. Biophys. Acta Mol. Cell Biol. Lipids* **2020**, *1865*, 158597. [CrossRef] [PubMed]

362. Uchida, D.; Takaki, A.; Adachi, T.; Okada, H. Beneficial and paradoxical roles of anti-oxidative nutritional support for non-alcoholic fatty liver disease. *Nutrients* **2018**, *10*, 977. [CrossRef] [PubMed]

363. Wang, X.; Anad, A.; Wu, Q.; Qiao, F.; Ares, I.; Yuan, Z. Mechanism of neonicotinoid toxicity: Impact on oxidative stress and metabolism. *Annu. Rev. Pharmacol. Toxicol.* **2018**, *58*, 471–507. [CrossRef] [PubMed]

364. Wang, X.; Martínez, M.A.; Dai, M.; Chen, D.; Ares, I.; Romero, A.; Castellano, V.; Martínez, M.; Rodríguez, J.L.; Martínez-Larrañaga, M.R.; et al. Permethrin-induced oxidative stress and toxicity and metabolism. A review. *Environ. Res.* **2016**, *149*, 86–104. [CrossRef] [PubMed]

365. Lu, Q.; Sun, Y.; Ares, I.; Anadón, A.; Martínez, M. Deltamethrin toxicity: A review of oxidative stress and metabolism. *Environ. Res.* **2019**, *170*, 260–281. [CrossRef] [PubMed]

366. Yang, J.S.; Symington, S.; Clark, J.M.; Park, Y.; Sciences, B.; Sciences, A. Permethrin, a pyrethroid insecticide, regulates ERK1/2 activation through membrane depolarization-mediated pathway in HepG2 hepatocytes. *Food Chem. Toxicol.* **2019**, *121*, 387–395. [CrossRef]

367. Mu, X.; Shen, G.; Huang, Y.; Luo, J.; Zhu, L.; Qi, S. The enantioselective toxicity and oxidative stress of beta-cypermethrin on zebra fish. *Environ. Pollut.* **2017**, *229*, 312–320. [CrossRef]

368. Jin, Y.; Wang, J.; Pan, X.; Wang, L.; Fu, Z. Cis-bifenthrin enantioselectively induces hepatic oxidative stress in mice. *Pestic. Biochem. Physiol.* **2013**, *107*, 61–67. [CrossRef]

369. Dar, M.A.; Khan, A.M.; Raina, R.; Verma, P.K.; Wani, N.M. Effect of bifenthrin on oxidative stress parameters in the liver, kidneys, and lungs of rats. *Environ. Sci. Pollut. Res.* **2019**, *26*, 9365–9370. [CrossRef]

370. Zhang, Y.; Lu, M.; Zhou, P.; Wang, C.; Zhang, Q.; Zhao, M. Multilevel evaluations of potential liver injury of bifenthrin. *Pestic. Biochem. Physiol.* **2015**, *122*, 29–37. [CrossRef]

371. Tuzmen, N.; Candan, N.; Kaya, E.; Demiryas, N. Biochemical effects of chlorpyrifos and deltamethrin on altered antioxidative defense mechanisms and lipid peroxidation in rat liver. *Cell Biochem. Funct.* **2008**, 119–124. [CrossRef] [PubMed]

372. Migliaccio, V.; Lionetti, L.; Putti, R.; Scudiero, R. Exposure to dichlorodiphenyldichloroethylene (DDE) and metallothionein levels in rats fed with normocaloric or high-fat diet: A review. *Int. J. Mol. Sci.* **2020**, *21*, 1903. [CrossRef] [PubMed]
373. Soudani, N.; Chaâbane, M.; Ghorbel, I.; Elwej, A.; Boudawara, T. Glyphosate disrupts redox status and up-regulates metallothionein I and II genes expression in the liver of adult rats. Alleviation by quercetin. *Gen. Physiol. Biophys.* **2019**, *123–134*. [CrossRef] [PubMed]

374. Bailey, D.C.; Todt, C.E.; Burchfield, S.L.; Pressley, A.S.; Denney, R.D.; Snapp, I.B.; Negga, R.; Traynor, W.L.; Fitsanakis, V.A. Chronic exposure to a glyphosate-containing pesticide leads to mitochondrial dysfunction and increased reactive oxygen species production in Caenorhabditis elegans. *Environ. Toxicol. Pharmacol.* **2018**, *57*, 46–52. [CrossRef] [PubMed]

375. Tayeb, W.; Nakbi, A.; Cheraief, I.; Miled, A.; Hammami, M. Alteration of lipid status and lipid metabolism, induction of oxidative stress and lipid peroxidation by 2,4-dichlorophenoxyacetic herbicide in rat liver. *Toxicol. Mech. Methods* **2013**, *23*, 449–458. [CrossRef] [PubMed]

376. de Oliveira, B.; Pereira, L.C.; Pazin, M.; Franco-Bernanrdes, M.F.; Dorta, D.J. Do trifluralin and tebuthiuron impair isolated rat liver mitochondria? *Pestic. Biochem. Physiol.* **2020**, *163*, 175–184. [CrossRef]

377. Ben Amara, I.; Ben Saad, H.; Hamdaoui, L.; Karray, A.; Boudawara, T.; Ben Ali, Y.; Zeghal, N. Maneb disturbs expression of superoxide dismutase and glutathione peroxidase, increases reactive oxygen species production, and induces genotoxicity in liver of adult mice. *Environ. Sci. Pollut. Res.* **2015**, *22*, 12309–12322. [CrossRef] [PubMed]

378. Han, Y.; Liu, T.; Wang, J.; Wang, J.; Zhang, C.; Zhu, L. Genotoxicity and oxidative stress induced by the fungicide azoxystrobin in zebra fish (Danio rerio) livers. *YPEST* **2016**, *133*, 13–19. [CrossRef]

379. Jia, W.; Mao, L.; Zhang, L.; Zhang, Y.; Jiang, H. Effects of two strobilurins (azoxystrobin and picoxystrobin) on embryonic development and enzyme activities in juveniles and adult fish livers of zebrafish (Danio rerio). *Chemosphere* **2018**, *207*, 573–580. [CrossRef] [PubMed]

380. Hamdi, H.; Othmène, Y.B.; Ammar, O.; Klifi, A.; Hallara, E.; Ghali, F.B.; Houas, Z.; Najjar, M.F.; Abid-Essefi, S. Oxidative stress, genotoxicity, biochemical and histopathological modifications induced by epoxiconazole in liver and kidney of wistar rats. *Environ. Sci. Pollut. Res.* **2019**, *26*, 17535–17547. [CrossRef]

381. Bruno, M.; Moore, T.; Nesnow, S.; Ge, Y. Protein carbonyl formation in response to propiconazole-induced oxidative stress. *J. Proteome Res.* **2009**, *8*, 2070–2078. [CrossRef] [PubMed]

382. Nesnow, S.; Padgett, W.T.; Moore, T. Propiconazole induces alterations in the hepatic metabolome of mice: Relevance to propiconazole-induced hepatocarcinogenesis. *Toxicol. Sci.* **2011**, *120*, 297–309. [CrossRef] [PubMed]

383. Di Yang, J.; Liu, S.H.; Liao, M.H.; Chen, R.M.; Liu, P.Y.; Ueng, T.H. Effects of tebuconazole on cytochrome P450 enzymes, oxidative stress, and endocrine disruption in male rats. *Environ. Toxicol.* **2018**, *33*, 899–907. [CrossRef] [PubMed]

384. Abolaji, A.O.; Awogbindin, I.O.; Adedara, I.A.; Farombi, E.O. Insecticide chlorpyrifos and fungicide carbendazim, common food contaminants mixture, induce hepatic, renal, and splenic oxidative damage in female rats. *Hum. Exp. Toxicol.* **2016**, *1–11*. [CrossRef] [PubMed]

385. Klaunig, J.E.; Kamendulis, L.M. THE role of oxidative stress in carcinogenesis. *Annu. Rev. Pharmacol. Toxicol.* **2004**, *44*, 239–267. [CrossRef] [PubMed]

386. Parke, D.V. The cytochromes P450 and mechanisms of chemical carcinogenesis. *Environ. Health Perspect.* **1994**, *102*, 852–853. [CrossRef]

387. Gonzalez, F.J. Role of cytochromes P450 in chemical toxicity and oxidative stress: Studies with CYP2E1. *Mutat. Res. Fundam. Mol. Mech. Mutagen.* **2005**, *569*, 101–110. [CrossRef]

388. Ibtissem, B.A.; Hajer, B.S.; Ahmed, H.; Awatef, E.; Choumous, K.; Ons, B.; Mounir, Z.K.; Najiba, Z. Oxidative stress and histopathological changes induced by methylthiophanate, a systemic fungicide, in blood, liver and kidney of adult rats. *Afr. Health Sci.* **2017**, *17*, 154–163. [CrossRef]

389. Hase, Y.; Tatsuno, M.; Nishi, T.; Kataoka, K. Atrazine binds to F1 F0 -ATP synthase and inhibits mitochondrial function in sperm. *Biochem. Biophys. Res. Comun.* **2008**, *366*, 66–72. [CrossRef]

390. Simões, S.; Bracht, L.; Parizotto, A.V.; Comar, J.F.; Peralta, R.M.; Bracht, A. The metabolic effects of diuron in the rat liver. *Environ. Toxicol. Pharmacol.* **2017**, *54*, 53–61. [CrossRef]

391. Gomes, M.P.; Juneau, P. Oxidative stress in duckweed (Lemna minor L.) induced by glyphosate: Is the mitochondrial electron transport chain a target of this herbicide? *Environ. Pollut.* **2016**, *218*, 402–409. [CrossRef]

392. Elmore, S.E.; La Merrill, M.A. Oxidative phosphorylation impairment by DDT and DDE. *Front. Endocrinol.* (Lausanne). **2019**, *10*. [CrossRef] [PubMed]
393. Salama, M.; El-Morsy, D.; El-Gamal, M.; Shabka, O.; Mohamed, W.M.Y. Mitochondrial complex I inhibition as a possible mechanism of chlorpyrifos induced neurotoxicity. *Ann. Neurosci.* **2014**, *21*, 85–89. [CrossRef] [PubMed]

394. Venkatesh, S.; Ramachandran, A.; Zachariah, A.; Oommen, A. Mitochondrial ATP synthase inhibition and nitric oxide are involved in muscle weakness that occurs in acute exposure of rats to monocrotophos. *Toxicol. Mech. Methods* **2009**, *19*, 239–245. [CrossRef] [PubMed]

395. Karami-Mohajeri, S.; Hadian, M.R.; Fouladdel, S.; Azizi, E.; Ghahramani, M.H.; Hosseini, R.; Abdollahi, M. Mechanisms of muscular electrophysiological and mitochondrial dysfunction following exposure to malathion, an organophosphorus pesticide. *Hum. Exp. Toxicol.* **2014**, *33*, 251–263. [CrossRef] [PubMed]

396. Castanha Zanoli, J.C.; Maioli, M.A.; Medeiros, H.C.D.; Mingatto, F.E. Abamectin affects the bioenergetics of liver mitochondria: A potential mechanism of hepatotoxicity. *Toxicol. Vitr.* **2012**, *26*, 51–56. [CrossRef] [PubMed]

397. Bizerra, P.F.V.; Guimarães, A.R.J.S.; Maioli, M.A.; Fábio, E. Imidacloprid affects rat liver mitochondrial bioenergetics by inhibiting F o F 1-ATP synthase activity. *J. Toxicol. Environ. Health Part A* **2018**, *1–11*. [CrossRef] [PubMed]

398. Bailey, D.C.; Todt, C.E.; Orfield, S.E.; Denney, R.D.; Snapp, I.B.; Negga, R.; Montgomery, K.M.; Bailey, A.C.; Pressley, A.S.; Traynor, W.L.; et al. Caenorhabditis elegans chronically exposed to a Mn/Zn ethylene-bis-dithiocarbamate fungicide show mitochondrial Complex I inhibition and increased reactive oxygen species. *Neurotoxicology* **2016**, *56*, 170–179. [CrossRef]

399. Bénit, P.; Kahn, A.; Chretien, D.; Bortoli, S.; Huc, L.; Schiff, M.; Gimenez-Roqueplo, A.P.; Favier, J.; Gressens, P.; Rak, M.; et al. Evolutionarily conserved susceptibility of the mitochondrial respiratory chain to SDHI pesticides and its consequence on the impact of SDHIs on human cultured cells. *PLoS ONE* **2019**, *14*, e0224132. [CrossRef]

400. Gomes, J.; Lloyd, O.L. Oral exposure of mice to formulations of organophosphorous pesticides: Gestational and litter outcomes. *Int. J. Environ. Health Res.* **2009**, *19*, 125–137. [CrossRef]

401. Brandhorst, T.T.; Klein, B.S. Uncertainty surrounding the mechanism and safety of the post-harvest fungicide fludioxonil. *Food Chem. Toxicol.* **2019**, *123*, 561–565. [CrossRef] [PubMed]

402. Shukla, S.; Singh, D.; Kumar, V.; Chauhan, A.K.; Singh, S.; Ahmad, I.; Pandey, H.P.; Singh, C. NADPH oxidase mediated maneb- and paraquat-induced oxidative stress in rat polymorphs: Crosstalk with mitochondrial dysfunction. *Pestic. Biochem. Physiol.* **2015**, *123*, 74–86. [CrossRef] [PubMed]

403. Jin, X.T.; Song, L.; Li, Z.Y.; Newton, I.P.; Zhao, M.R.; Liu, W.P. Dichlorodiphenyldichloroethylene exposure reduces r-GCS via suppressed Nrf2 in HepG2 cells. *Environ. Toxicol.* **2016**, *31*, 350–359. [CrossRef] [PubMed]

404. Hernandez-Cortes, D.; Alvarado-Cru, I.; Solís-Heredia, M.J.; Quintanilla-Vega, B. Epigenetic modulation of Nrf2 and Ogg1 gene expression in testicular germ cells by methyl parathion exposure. *Toxicol. Appl. Pharmacol.* **2018**, *346*, 19–27. [CrossRef] [PubMed]

405. Gargouri, B.; Yousif, N.M.; Attaai, A.; Bouchard, M. Neurochemistry International pyrethroid bifenthrin induces oxidative stress, neuroinflammation, and neuronal damage, associated with cognitive and memory impairment in murine hippocampus. *Neurochem. Int.* **2018**, *120*, 121–133. [CrossRef] [PubMed]

406. Lundqvist, J.; Hellman, B.; Oskarsson, A. Fungicide prochloraz induces oxidative stress and DNA damage in vitro. *Food Chem. Toxicol.* **2016**, *91*, 36–41. [CrossRef] [PubMed]

407. Sagarkar, S.; Gandhi, D.; Devi, S.; Sakharkar, A.; Kapley, A. atrazin exposure causes mitochondrial toxicity in liver and muscle cell lines. *Indian J. Pharmacol.* **2016**, *48*, 200–207. [CrossRef] [PubMed]

408. Pu, M.Z.; Zhao, Y.L. Chlorpyrifos activates cell pyroptosis and increases susceptibility on oxidative stress-induced toxicity by miR-181/SIRT1/PGC-1 α/Nrf2 signaling pathway in human neuroblastoma SH-SY5Y cells. *Environ. Toxicol.* **2019**, *699–707*. [CrossRef]

409. Xie, L.; Li, X.; Mo, J.; Li, L.; Chen, X.; Chen, L.; Ma, L.; Chen, Y.; Ge, F.; Zhao, J.; et al. Delayed puberty by ziram is associated with down regulation of testicular phosphorylated AKT1 and SIRT1/PGC-1α signaling. *Chem. Res. Toxicol.* **2018**, *31*, 1315–1322. [CrossRef]

410. Gorczyca, G.; Wartalski, K.; Tabarowski, Z.; Duda, M. Effects of vinclozolin exposure on the expression and activity of SIRT1 and SIRT6 in the porcine ovary. *J. Physiol. Pharmacol.* **2019**, *70*, 153–165. [CrossRef]

411. Li, S.; Zhao, G.; Chen, L.; Ding, Y.; Lian, J.; Hong, G.; Lu, Z. Resveratrol protects mice from paraquat-induced lung injury: The important role of SIRT1 and Nrf2 antioxidant pathways. *Mol. Med. Rep.* **2016**, *13*, 1833–1838. [CrossRef] [PubMed]
412. Deng, J.Z.Y.; Zhang, M.; Su, H. SIRT3 Acts as a neuroprotective agent in rotenone-induced parkinson cell model. *Neurochem. Res.* **2016**. [CrossRef]

413. Mostafalou, S.; Abdollahi, M. Pesticides and human chronic diseases: Evidences, mechanisms, and perspectives. *Toxicol. Appl. Pharmacol.* **2013**, *268*, 157–177. [CrossRef] [PubMed]

414. Weng, S.; Zhou, L.; Deng, Q.; Wang, J.; Yu, Y.; Zhu, J.; Yuan, Y. Niclosamide induced cell apoptosis via upregulation of ATF3 and activation of PERK in hepatocellular carcinoma cells. *BMC Gastroenterol.* **2016**, *16*, 1–10. [CrossRef] [PubMed]

415. Mesnage, R.; Biserni, M.; Balu, S.; Frainay, C.; Poupin, N.; Jourdan, F.; Wozniak, E.; Xenakis, T.; Mein, C.A.; Antoniou, M.N. Integrated transcriptomics and metabolomics reveal signatures of lipid metabolism dysregulation in HepaRG liver cells exposed to PCB 126. *Arch. Toxicol.* **2018**, *92*, 2533–2547. [CrossRef] [PubMed]

416. Lemaire, G.; Mnif, W.; Pascussi, J.M.; Pillon, A.; Rabenoelina, F.; Fenet, H.; Gomez, E.; Casellas, C.; Nicolas, J.C.; Cavaillès, V.; et al. Identification of new human pregnane X receptor ligands among pesticides using a stable reporter cell system. *Toxicol. Sci.* **2006**, *91*, 501–509. [CrossRef] [PubMed]

417. Yoshimaru, S.; Shizu, R.; Tsuruta, S.; Amaike, Y.; Kano, M.; Hosaka, T.; Sasaki, T.; Yoshinari, K. Acceleration of murine hepatocyte proliferation by imazalil through the activation of nuclear receptor PXR. *J. Toxicol. Sci.* **2018**, *43*, 443–450. [CrossRef]

418. Luckert, C.; Braeuning, A.; De Sousa, G.; Durinck, S.; Katsanou, E.S.; Konstantinidou, P.; Machera, K.; Milani, E.S.; Peijnenburg, A.A.C.M.; Rahmani, R.; et al. Adverse outcome pathway-driven analysis of liver steatosis in vitro: A case study with cyproconazole. *Chem. Res. Toxicol.* **2018**, *31*, 784–798. [CrossRef]

419. Toporova, L.B.P. Nuclear receptors are the major targets of endocrine disrupting chemicals. *Mol. Cell. Endocrinol.* **2020**, *502*, 165. [CrossRef]

420. Genoa, R.W.; Mourikes, V.N.A.B.E.F.J. Mechanisms of action of agrochemicals acting as endocrine disrupting chemicals. *Mol. Cell. Endocrinol.* **2020**, *502*, 110680. [CrossRef]

421. Oseini, A.M.; Sanyal, A.J. Therapies in non-alcoholic steatohepatitis (NASH). *Liver Int.* **2017**, *37*, 97–103. [CrossRef] [PubMed]

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

<figure><img src="image_11.png" /></figure>

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).